Statement from the National Kidney Foundation on FDA Communication Regarding Hemodialysis Bloodlines
Washington, DC (April 11, 2025) - The U.S. Food and Drug Administration (FDA) has asked the National Kidney Foundation to assist in sharing important information with the kidney community about a shortage of devices for hemodialysis.
The FDA has issued a communication to healthcare providers regarding disruptions in the availability of hemodialysis bloodlines, which are critical components of dialysis care. We encourage providers, patients, and other stakeholders to review the FDA’s letter and stay informed about any potential impacts to dialysis treatment and supply availability.
View the full letter here:
https://www.fda.gov/medical-devices/letters-health-care-providers/disruptions-availability-hemodialysis-bloodlines-letter-health-care-providers
We will continue to monitor this issue and provide updates as needed. If you have any information or questions about this device shortage, please contact the FDA at (888) 463-6332 or visit FDA.gov.